Global LAG-3 Targeting Therapy Market Size, Approved Therapy Dosage, Patent, Sales & Clinical Trials Insight 2031
Findings & Highlights:
The global market for anti-LAG-3 therapy has advanced to the commercial stage from being experimental, on account of the availability of the first-in-class anti-LAG-3 therapy that has received regulatory approval. The only approved drug in this category of therapies is Opdualag, representing the first clinical validation of LAG-3 as an actionable checkpoint in immunotherapies beyond just PD-1 and CTLA-4. It serves as the basis for the development of future combinations in immunotherapy treatment.
However, despite its relatively early market stage, it has experienced high performance, registering global sales exceeding US$ 1 Billion in 2025, on account of rapid uptake in melanoma therapy applications as well as physicians' acceptance of dual checkpoint inhibitors. Currently, the leading revenue generator in the market is the US, as it was the early adopter of anti-LAG-3 therapies and benefits from high immunotherapy uptake. However, there remains a high degree of market concentration, with substantial growth potential anticipated due to new indications and combinations being brought into the fold.
The objective of this report is to offer investors, pharmaceutical organizations, and other parties a systematic outlook on the developing LAG-3 space. The report encompasses information on its commercial success, clinical trends, competition, and future growth prospects within the field.
Clinical Trials Insight Included In Report
The report offers a comprehensive understanding of the latest developments in the clinical development of LAG-3 targeting molecules, allowing interested parties to make an assessment of the clinical advancement of this novel immune checkpoint. This report covers clinical studies at various stages of development, including early-stage clinical studies and later-stage clinical studies, including registration-stage clinical trials. The report mainly covers the use of LAG-3 targeting agents to overcome resistance in existing immunotherapy treatment options for patients with solid tumors, including melanoma, NSCLC, gastric cancer, and head and neck cancers.
Combination therapies remain the main approach in the clinical development of LAG-3 targeting therapies, specifically LAG-3 and PD-1 inhibition. Further expanding on the concept of combination immunotherapies, late-stage drugs like fianlimab in combination with cemiplimab is undergoing trials for its potential treatment of melanoma and non-small cell lung cancer, whereas new bispecific drugs targeting PD-1 and LAG-3 simultaneously are currently under investigation to boost the activity of the immune system with a single drug. The other promising area of immunotherapy studies includes triple therapy that involves a combination of LAG-3, PD-1, and CTLA-4, among other innovative forms of therapy such as cancer vaccines and oncolytic viruses.
Major Companies Driving LAG-3 Targeting Therapies R&D
The landscape of LAG-3 is driven by large pharmaceutical firms in conjunction with biotechnology firms. Major players, for instance, BMS, Regeneron, and others, are using their existing immuno-oncology backbone to explore LAG-3 combinations across different cancer types. Their main emphasis is to work on clinical trial stages beyond Phase II and also explore label extension.
On the other hand, the small biotech companies, like Y-Biologics, Immutep, and Fontacea Pharmaceutical, are involved in early stage innovations and developments. These biotech firms are working on the use of bispecific and multispecific antibodies. This can be seen in projects involving the LAG-3 pathway in combination with the TIGIT or TIM-3 pathways.
These collaborations are crucial in shaping the industry landscape. Biotech companies are collaborating with big players in the pharmaceutical industry. This helps in speeding up development processes as well as conducting clinical trials through various partnerships.
Future Outlook For LAG-3 Targeting Therapies
Future market growth is expected to come largely from indications outside of melanoma, as multiple clinical trials are underway for NSCLC, colorectal cancer, gastric cancer, and other solid tumors. As the evidence base develops, the expectation is that LAG-3 inhibitors will become components of more expansive first-line immunotherapy combinations in certain cancer types.
Biomarker-based patient selection is another potential second growth driver. In contrast to previous checkpoint inhibitors, LAG-3 inhibitors are being tested in well-defined immune phenotypes, which should increase efficacy and refine positioning strategies. This should help to facilitate better reimbursement and adoption dynamics.
From an investment and pharma company perspective, LAG-3 provides an early-stage immunotherapy category that has begun to de-risk. Given one approved drug's sales surpassing USD 1 Billion per year (2025), the category appears to be entering its early phases of a multiphase expansion cycle akin to previous checkpoint inhibitor categories, providing both short-term commercial clarity and long-term pipeline potential.
- Global LAG-3 Targeting Therapy Market Opportunity: > USD 5 Billion By 2031
- Global Market Size Insight: 2022 Till 2031
- Approved LAG-3 Targeting Therapy Dosage, Pricing & Sales Insight
- Annual & Quarterly Sales Insight: 2022 – Q1’2026
- Insight On LAG-3 Targeting Therapies In Clinical Trials: > 35 Therapies
- LAG-3 Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase
- Key LAG-3 Targeting Therapies Initiation & Completion Year
- Competitive Landscape
The global market for anti-LAG-3 therapy has advanced to the commercial stage from being experimental, on account of the availability of the first-in-class anti-LAG-3 therapy that has received regulatory approval. The only approved drug in this category of therapies is Opdualag, representing the first clinical validation of LAG-3 as an actionable checkpoint in immunotherapies beyond just PD-1 and CTLA-4. It serves as the basis for the development of future combinations in immunotherapy treatment.
However, despite its relatively early market stage, it has experienced high performance, registering global sales exceeding US$ 1 Billion in 2025, on account of rapid uptake in melanoma therapy applications as well as physicians' acceptance of dual checkpoint inhibitors. Currently, the leading revenue generator in the market is the US, as it was the early adopter of anti-LAG-3 therapies and benefits from high immunotherapy uptake. However, there remains a high degree of market concentration, with substantial growth potential anticipated due to new indications and combinations being brought into the fold.
The objective of this report is to offer investors, pharmaceutical organizations, and other parties a systematic outlook on the developing LAG-3 space. The report encompasses information on its commercial success, clinical trends, competition, and future growth prospects within the field.
Clinical Trials Insight Included In Report
The report offers a comprehensive understanding of the latest developments in the clinical development of LAG-3 targeting molecules, allowing interested parties to make an assessment of the clinical advancement of this novel immune checkpoint. This report covers clinical studies at various stages of development, including early-stage clinical studies and later-stage clinical studies, including registration-stage clinical trials. The report mainly covers the use of LAG-3 targeting agents to overcome resistance in existing immunotherapy treatment options for patients with solid tumors, including melanoma, NSCLC, gastric cancer, and head and neck cancers.
Combination therapies remain the main approach in the clinical development of LAG-3 targeting therapies, specifically LAG-3 and PD-1 inhibition. Further expanding on the concept of combination immunotherapies, late-stage drugs like fianlimab in combination with cemiplimab is undergoing trials for its potential treatment of melanoma and non-small cell lung cancer, whereas new bispecific drugs targeting PD-1 and LAG-3 simultaneously are currently under investigation to boost the activity of the immune system with a single drug. The other promising area of immunotherapy studies includes triple therapy that involves a combination of LAG-3, PD-1, and CTLA-4, among other innovative forms of therapy such as cancer vaccines and oncolytic viruses.
Major Companies Driving LAG-3 Targeting Therapies R&D
The landscape of LAG-3 is driven by large pharmaceutical firms in conjunction with biotechnology firms. Major players, for instance, BMS, Regeneron, and others, are using their existing immuno-oncology backbone to explore LAG-3 combinations across different cancer types. Their main emphasis is to work on clinical trial stages beyond Phase II and also explore label extension.
On the other hand, the small biotech companies, like Y-Biologics, Immutep, and Fontacea Pharmaceutical, are involved in early stage innovations and developments. These biotech firms are working on the use of bispecific and multispecific antibodies. This can be seen in projects involving the LAG-3 pathway in combination with the TIGIT or TIM-3 pathways.
These collaborations are crucial in shaping the industry landscape. Biotech companies are collaborating with big players in the pharmaceutical industry. This helps in speeding up development processes as well as conducting clinical trials through various partnerships.
Future Outlook For LAG-3 Targeting Therapies
Future market growth is expected to come largely from indications outside of melanoma, as multiple clinical trials are underway for NSCLC, colorectal cancer, gastric cancer, and other solid tumors. As the evidence base develops, the expectation is that LAG-3 inhibitors will become components of more expansive first-line immunotherapy combinations in certain cancer types.
Biomarker-based patient selection is another potential second growth driver. In contrast to previous checkpoint inhibitors, LAG-3 inhibitors are being tested in well-defined immune phenotypes, which should increase efficacy and refine positioning strategies. This should help to facilitate better reimbursement and adoption dynamics.
From an investment and pharma company perspective, LAG-3 provides an early-stage immunotherapy category that has begun to de-risk. Given one approved drug's sales surpassing USD 1 Billion per year (2025), the category appears to be entering its early phases of a multiphase expansion cycle akin to previous checkpoint inhibitor categories, providing both short-term commercial clarity and long-term pipeline potential.
1. RESEARCH METHODOLOGY
2. INTRODUCTION TO LAG-3 TARGETING THERAPIES
2.1 LAG-3 As Therapeutic Target
2.2 LAG-3 Targeting Therapies - Mechanism Of Action
2.3 LAG-3 Targeting Approaches
3. COMBINATION STRATEGIES FOR LAG-3 TARGETING THERAPIES
4. GLOBAL LAG-3 TARGETING THERAPY MARKET SCENARIO
4.1 Current Market Outlook
4.2 Future Market Outlook
5. LAG-3 TARGETING THERAPY MARKET REGIONAL ANALYSIS
5.1 US
5.2 EU
5.3 China
5.4 Australia
5.5 UK
5.6 Japan
5.7 Canada
5.8 South Korea
6. OPDUALAG (NIVOLUMAB & RELATLIMAB) - OVERVIEW, PRICING, DOSING & SALES ANALYSIS
6.1 Overview & Patent Insight
6.2 Pricing & Dosing
6.3 Sales Insight
7. GLOBAL LAG-3 TARGETING THERAPIES CLINICAL TRIALS OVERVIEW
7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
8. GLOBAL LAG-3 TARGETING THERAPIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III
9. MARKETED LAG3 INHIBITOR CLINICAL INSIGHT
10. LAG-3 TARGETING THERAPY - DEVELOPMENT TRENDS BY INDICATION
10.1 Cancer
10.1.1 Hematological Malignancies
10.1.2 Solid Tumors
10.2 Autoimmune & Inflammatory Diseases
10.3 Microbial Infections
11. GLOBAL LAG-3 TARGETING THERAPY MARKET DYNAMICS
11.1 Market Drivers
11.2 Market Challenges
12. COMPETITIVE LANDSCAPE
12.1 ABL Bio
12.2 Agenus
12.3 Akeso Biopharma
12.4 Bristol-Myers Squibb
12.5 EpimAb Biotherapeutics
12.6 Immutep
12.7 Innovent Biologics
12.8 Regeneron
12.9 Shanghai Henlius Biotech
12.10 Y-Biologics
2. INTRODUCTION TO LAG-3 TARGETING THERAPIES
2.1 LAG-3 As Therapeutic Target
2.2 LAG-3 Targeting Therapies - Mechanism Of Action
2.3 LAG-3 Targeting Approaches
3. COMBINATION STRATEGIES FOR LAG-3 TARGETING THERAPIES
4. GLOBAL LAG-3 TARGETING THERAPY MARKET SCENARIO
4.1 Current Market Outlook
4.2 Future Market Outlook
5. LAG-3 TARGETING THERAPY MARKET REGIONAL ANALYSIS
5.1 US
5.2 EU
5.3 China
5.4 Australia
5.5 UK
5.6 Japan
5.7 Canada
5.8 South Korea
6. OPDUALAG (NIVOLUMAB & RELATLIMAB) - OVERVIEW, PRICING, DOSING & SALES ANALYSIS
6.1 Overview & Patent Insight
6.2 Pricing & Dosing
6.3 Sales Insight
7. GLOBAL LAG-3 TARGETING THERAPIES CLINICAL TRIALS OVERVIEW
7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
8. GLOBAL LAG-3 TARGETING THERAPIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III
9. MARKETED LAG3 INHIBITOR CLINICAL INSIGHT
10. LAG-3 TARGETING THERAPY - DEVELOPMENT TRENDS BY INDICATION
10.1 Cancer
10.1.1 Hematological Malignancies
10.1.2 Solid Tumors
10.2 Autoimmune & Inflammatory Diseases
10.3 Microbial Infections
11. GLOBAL LAG-3 TARGETING THERAPY MARKET DYNAMICS
11.1 Market Drivers
11.2 Market Challenges
12. COMPETITIVE LANDSCAPE
12.1 ABL Bio
12.2 Agenus
12.3 Akeso Biopharma
12.4 Bristol-Myers Squibb
12.5 EpimAb Biotherapeutics
12.6 Immutep
12.7 Innovent Biologics
12.8 Regeneron
12.9 Shanghai Henlius Biotech
12.10 Y-Biologics
LIST OF TABLES
Table 3-1: Ongoing Preclinical & Clinical Trials For Combination of LAG-3 inhibitors
Table 5-1: Immutep – Active Patents By Region
Table 6-1: Opdualag - Maximum Infusion Volumes & Concentration Ranges By Patient Group
Table 6-2: Opdualag - Recommended Dosage Modifications For Adverse Reactions
Table 3-1: Ongoing Preclinical & Clinical Trials For Combination of LAG-3 inhibitors
Table 5-1: Immutep – Active Patents By Region
Table 6-1: Opdualag - Maximum Infusion Volumes & Concentration Ranges By Patient Group
Table 6-2: Opdualag - Recommended Dosage Modifications For Adverse Reactions
LIST OF FIGURES
Figure 2-1: LAG-3/MHC Class II Signaling Pathway
Figure 2-2: LAG-3 Targeted Therapy Landscape - Milestones
Figure 2-3: LAG-3 Inhibitor – Mechanism Of Action
Figure 2-4: LAG-3 Agonist – Mechanism Of Action
Figure 2-5: LAG-3 Depletion – Mechanism Of Action
Figure 2-6: Bispecific Antibodies - Binding Efficacy
Figure 3 1: Possible LAG-3 Combinations
Figure 4-1: Global – LAG 3 Targeting Therapy Market (US$ Million), 2022-2026
Figure 4-2: Global – LAG 3 Targeting Therapy Market By Region (US$ Million), Q1’2026
Figure 4-3: Global – LAG 3 Targeting Therapy Market By Region (US$ Million), 2025
Figure 4-4: Global – Quarterly LAG 3 Targeting Therapy Market (US$ Million), 2025
Figure 4-5: Global – LAG 3 Targeting Therapy Market By Region (%), 2024
Figure 4-6: Global – LAG 3 Targeting Therapy Market Forecast (US$ Million), 2026-2031
Figure 4-7: Global LAG-3 Targeting Therapy Market - Future Outlook
Figure 5-1: EU - Research Institutes & Hospitals Conducting LAG-3 Therapy Clinical Trials
Figure 6-1: Opdualag – Approval Year by Region
Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Year By Region
Figure 6-3: US – Cost Per Unit & Supply Of Opdualag (US$), May’2026
Figure 6-4: UK - Cost Per Unit & Supply Of Opdualag (US$), May’2026
Figure 6-5: Global – Opdualag Annual Sales (US$ Million), 2022-2026
Figure 6-6: Global – Opdualag Annual Sales By Region (US$ Million), Q1’2026
Figure 6-7: Global – Opdualag Quarterly Sales (US$ Million), 2025
Figure 6-8: US – Opdualag Annual Sales (US$ Million), 2024-2026
Figure 6-9: US – Opdualag Quarterly Sales (US$ Million), 2025
Figure 6-10: ROW – Opdualag Sales (US$ Million), 2024-2026
Figure 6-11: ROW – Opdualag Quarterly Sales (US$ Million), 2025
Figure 6-12: Opdualag – US v/s ROW Sales (US$ Million), 2024
Figure 6-13: Global – Opdualag Sales (US$ Million), 2024
Figure 6-14: US – Opdualag Sales (US$ Million), 2022-2024
Figure 6-15: US – Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 6-16: ROW – Opdualag Sales (US$ Million), 2022-2024
Figure 6-17: ROW – Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 7-1: Global – LAG-3 Inhibitor Clinical Trials By Phase (Numbers), 2026-2031
Figure 7-2: Global – LAG-3 Inhibitor Clinical Trials By Country (Numbers), 2026-2031
Figure 7-3: Global – LAG-3 Inhibitor Clinical Trials By Company (Numbers), 2026-2031
Figure 7-4: Global – LAG-3 Inhibitor Clinical Trials By Indication (Numbers), 2026-2031
Figure 7-5: Global – LAG-3 Inhibitor Clinical Trials By Priority Status (Numbers), 2026-2031
Figure 10-1: RELATIVITY-047 Phase 2/3 (NCT03470922) Study – Initiation & Completion Year
Figure 10-2: AK129-102 Phase 1/2 (NCT06642792) Study – Initiation & Completion Year
Figure 10-3: AK129-102 Phase 1/2 (NCT05137054) Study – Initiation & Completion Year
Figure 10-4: R3767-ONC-2235 Phase 2/3 (NCT05785767) Study – Initiation & Completion Year
Figure 10-5: R3767-ONC-2236 Phase 2/3 (NCT05800015) Study – Initiation & Completion Year
Figure 10-6: R2810-ONC-1866 Phase 2 (NCT03916627) Study – Initiation & Completion Year
Figure 10-7: R2810-ONC-2266 Phase 2 (NCT06161441) Study – Initiation & Completion Year
Figure 10-8: J23155 Phase 2 (NCT06205836) Study – Initiation & Completion Year
Figure 10-9: RELATIVITY-104 Phase 2 (NCT04623775) Study – Initiation & Completion Year
Figure 10-10: RELATIVITY-1093 Phase 3 (NCT06561386) Study – Initiation & Completion Year
Figure 10-11: J1714 Phase 1b (NCT03044613) Study – Initiation & Completion Year
Figure 10-12: HCC 18-139 Phase 2 (NCT04080804) Study – Initiation & Completion Year
Figure 10-13: CA209-1451 Phase 2 (NCT06624475) Study – Initiation & Completion Year
Figure 10-14: MIA2023/490 Phase 2 (NCT06288191) Study – Initiation & Completion Year
Figure 10-15: MIA2023/489 Phase 2 (NCT06151236) Study – Initiation & Completion Year
Figure 10-16: IMP761-P001 Phase 1 (NCT06637865) Study – Initiation & Completion Year
Figure 11-1: Global LAG-3 Targeting Therapy Market - Drivers & Opportunities
Figure 11-2: Global LAG-3 Targeting Therapy Market - Challenges & Restraints
Figure 2-1: LAG-3/MHC Class II Signaling Pathway
Figure 2-2: LAG-3 Targeted Therapy Landscape - Milestones
Figure 2-3: LAG-3 Inhibitor – Mechanism Of Action
Figure 2-4: LAG-3 Agonist – Mechanism Of Action
Figure 2-5: LAG-3 Depletion – Mechanism Of Action
Figure 2-6: Bispecific Antibodies - Binding Efficacy
Figure 3 1: Possible LAG-3 Combinations
Figure 4-1: Global – LAG 3 Targeting Therapy Market (US$ Million), 2022-2026
Figure 4-2: Global – LAG 3 Targeting Therapy Market By Region (US$ Million), Q1’2026
Figure 4-3: Global – LAG 3 Targeting Therapy Market By Region (US$ Million), 2025
Figure 4-4: Global – Quarterly LAG 3 Targeting Therapy Market (US$ Million), 2025
Figure 4-5: Global – LAG 3 Targeting Therapy Market By Region (%), 2024
Figure 4-6: Global – LAG 3 Targeting Therapy Market Forecast (US$ Million), 2026-2031
Figure 4-7: Global LAG-3 Targeting Therapy Market - Future Outlook
Figure 5-1: EU - Research Institutes & Hospitals Conducting LAG-3 Therapy Clinical Trials
Figure 6-1: Opdualag – Approval Year by Region
Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Year By Region
Figure 6-3: US – Cost Per Unit & Supply Of Opdualag (US$), May’2026
Figure 6-4: UK - Cost Per Unit & Supply Of Opdualag (US$), May’2026
Figure 6-5: Global – Opdualag Annual Sales (US$ Million), 2022-2026
Figure 6-6: Global – Opdualag Annual Sales By Region (US$ Million), Q1’2026
Figure 6-7: Global – Opdualag Quarterly Sales (US$ Million), 2025
Figure 6-8: US – Opdualag Annual Sales (US$ Million), 2024-2026
Figure 6-9: US – Opdualag Quarterly Sales (US$ Million), 2025
Figure 6-10: ROW – Opdualag Sales (US$ Million), 2024-2026
Figure 6-11: ROW – Opdualag Quarterly Sales (US$ Million), 2025
Figure 6-12: Opdualag – US v/s ROW Sales (US$ Million), 2024
Figure 6-13: Global – Opdualag Sales (US$ Million), 2024
Figure 6-14: US – Opdualag Sales (US$ Million), 2022-2024
Figure 6-15: US – Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 6-16: ROW – Opdualag Sales (US$ Million), 2022-2024
Figure 6-17: ROW – Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 7-1: Global – LAG-3 Inhibitor Clinical Trials By Phase (Numbers), 2026-2031
Figure 7-2: Global – LAG-3 Inhibitor Clinical Trials By Country (Numbers), 2026-2031
Figure 7-3: Global – LAG-3 Inhibitor Clinical Trials By Company (Numbers), 2026-2031
Figure 7-4: Global – LAG-3 Inhibitor Clinical Trials By Indication (Numbers), 2026-2031
Figure 7-5: Global – LAG-3 Inhibitor Clinical Trials By Priority Status (Numbers), 2026-2031
Figure 10-1: RELATIVITY-047 Phase 2/3 (NCT03470922) Study – Initiation & Completion Year
Figure 10-2: AK129-102 Phase 1/2 (NCT06642792) Study – Initiation & Completion Year
Figure 10-3: AK129-102 Phase 1/2 (NCT05137054) Study – Initiation & Completion Year
Figure 10-4: R3767-ONC-2235 Phase 2/3 (NCT05785767) Study – Initiation & Completion Year
Figure 10-5: R3767-ONC-2236 Phase 2/3 (NCT05800015) Study – Initiation & Completion Year
Figure 10-6: R2810-ONC-1866 Phase 2 (NCT03916627) Study – Initiation & Completion Year
Figure 10-7: R2810-ONC-2266 Phase 2 (NCT06161441) Study – Initiation & Completion Year
Figure 10-8: J23155 Phase 2 (NCT06205836) Study – Initiation & Completion Year
Figure 10-9: RELATIVITY-104 Phase 2 (NCT04623775) Study – Initiation & Completion Year
Figure 10-10: RELATIVITY-1093 Phase 3 (NCT06561386) Study – Initiation & Completion Year
Figure 10-11: J1714 Phase 1b (NCT03044613) Study – Initiation & Completion Year
Figure 10-12: HCC 18-139 Phase 2 (NCT04080804) Study – Initiation & Completion Year
Figure 10-13: CA209-1451 Phase 2 (NCT06624475) Study – Initiation & Completion Year
Figure 10-14: MIA2023/490 Phase 2 (NCT06288191) Study – Initiation & Completion Year
Figure 10-15: MIA2023/489 Phase 2 (NCT06151236) Study – Initiation & Completion Year
Figure 10-16: IMP761-P001 Phase 1 (NCT06637865) Study – Initiation & Completion Year
Figure 11-1: Global LAG-3 Targeting Therapy Market - Drivers & Opportunities
Figure 11-2: Global LAG-3 Targeting Therapy Market - Challenges & Restraints
